Dr Agarwals Health Care LtdNSE: AGARWALEYE
Open the Dr Agarwals Health Care Ltd page
Follow Dr Agarwals Health Care LtdFree account. Get a note when Dr Agarwals Health Care Ltd files.
Q1 FY27 results analysis · August 04, 2026

Dr Agarwals Health Care Ltd (AGARWALEYE) Q1 FY27 Results Analysis: PAT Surges 50.5%, Facility Additions Ahead of Schedule

+44.6%PAT year on year, Rs. 55.02 Cr
Cofacto ResearchPublished August 04, 20262 min read
Quick summary

Dr Agarwals Health Care Ltd reported Q1 FY27 numbers with revenue of Rs. 614.02 Cr (+26.00% YoY) and PAT growth of +44.60% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 04, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 614.02 Cr (+26.00% YoY)
PAT (Q1)Rs. 55.02 Cr (+44.60% YoY)
EBITDA margin28.50% (+30 bps YoY)
EPS (Q1)Rs. 1.43 (+50.50% YoY)
Market capRs. 15,630.69 Cr
CMPRs. 493.50

Quarter Snapshot

Revenue grew 26% YoY, beating management's ~21% guidance, and PAT-to-owners surged 50.5% YoY. The company added 18 new facilities in Q1, ahead of schedule, while maintaining stable EBITDA margins. Strong mature-facility growth and debt reduction from IPO proceeds support a positive outlook.

Key Investment Insights

Key Positives

  • Revenue grew 26.0% YoY to Rs.614.02 Cr, exceeding management's ~21% growth guidance
  • PAT attributable to owners grew 50.5% YoY to Rs.45.23 Cr
  • Added 18 new facilities in Q1, including a record 16 surgical facilities, ahead of the FY27 target run-rate
  • EBITDA margin remained stable at 28.5% (Total Income basis) despite aggressive greenfield expansion
  • Surgery volumes grew 15.5% YoY to 91,082 procedures, with favorable surgical mix shift toward higher-ASP procedures
  • Mature Facilities revenue grew 37.1% YoY to Rs.485 Cr, indicating strong same-store performance
  • Finance costs declined 5.4% YoY due to debt repayment from IPO proceeds

Risk Factors

  • Depreciation expense rose 24.4% YoY to Rs.78.31 Cr, reflecting the heavy capex of prior years, which will continue to weigh on net profit
  • Other income fell 52.1% YoY to Rs.6.41 Cr as IPO proceeds were deployed, reducing interest income
  • Standalone EBITDA margin compressed 60 bps to 25.9% (vs 26.5% in Q1FY26), indicating margin pressure at the standalone level
  • GST show cause notice of Rs.20.50 Cr received, though management does not expect financial impact

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.